Surrozen has cleared its IND for SZN-8141, a bifunctional antibody that simultaneously activates Frizzled 4-mediated Wnt signaling and blocks vascular endothelial growth factor, delivered by intravitreal injection for diabetic macular edema. The Phase 1b/2a DUET study will compare two dose levels against Vabysmo in approximately 60 treatment-naïve patients, with first dosing expected in late 2026 and initial data in the second half of 2027. The dual mechanism is intended to restore barrier function in damaged retinal vasculature rather than only suppress leakage, a shift from symptom control toward tissue repair.
Key Points
- Bifunctional antibody combines Wnt activation with VEGF blockade
- Preclinical work showed normal retinal vessel regrowth, suppressed pathological growth
- Phase 1b/2a compares two doses against Vabysmo in 60 patients
Longevity Analysis
Diabetic macular edema is a downstream consequence of chronic metabolic dysregulation acting on the smallest vessels, where sustained hyperglycemia degrades the blood-retinal barrier. Current anti-VEGF therapy suppresses the leakage signal without rebuilding the compromised vessel wall; adding Wnt pathway activation targets the structural repair itself, aligning treatment with the tissue's own regenerative machinery. The retina remains a visible proxy for microvascular integrity throughout the body, and approaches that restore rather than merely suppress may inform how circulatory damage is addressed in other organs where early signals are far harder to observe.
Original published by LT Wire.